XML 80 R17.htm IDEA: XBRL DOCUMENT v3.21.2
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SCHEDULE OF DISAGGREGATED REVENUE

For the three and nine months ended September 30, 2021 and 2020, the Company had the following disaggregated revenue:

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2021   %   2020   %   2021   %   2020   % 
                                 
Telehealth revenue  $18,540,897    74%  $9,438,136    86%  $47,623,822    73%  $20,263,750    83%
WorkSimpli revenue   6,406,302    26%   1,567,627    14%   17,835,100    27%   4,136,608    17%
Total net revenue  $24,947,199    100%  $11,005,763    100%  $65,458,922    100%  $24,400,358    100%
SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY

The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the in-process monthly or yearly contracts with customers and a portion attributable to the yet to be recognized initial 14-day trial period collections.

 

   2021   2020   2021   2020 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2021   2020   2021   2020 
Beginning of period  $1,381,938   $303,670   $916,880   $109,552 
Additions   6,020,061    1,695,017    17,233,084    3,833,386 
Revenue recognized   5,966,018    1,586,071    16,713,983    3,530,322 
End of period  $1,435,981   $412,616   $1,435,981   $412,616 
SUMMARY OF INVENTORY

As of September 30, 2021 and December 31, 2020, the Company’s inventory consisted of the following:

 

   September 30, 2021   December 31, 2020 
         
Finished goods - products  $1,570,519    1,172,624 
Raw materials and packaging components   74,056    149,115 
Inventory reserve   (57,481)   (57,481)
Total Inventory - net  $1,587,094   $1,264,258 
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price could be less than the average market price of the common shares:

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2021   2020   2021   2020 
                 
Series B Preferred Stock   1,076,923    -    1,076,923    - 
Restricted Stock Units (RSUs)   996,375    -    569,417    - 
Stock options   4,170,900    3,423,400    4,193,100    3,920,467 
Warrants   3,888,438    2,507,758    3,807,899    2,280,677 
Potentially dilutive securities   10,132,636    5,931,158    9,647,339    6,201,144